



Veterans Health Administration
Research & Development

Improving Veterans' Lives www.research.va.gov

VA's Impact on Advancing the Nation's Medical Knowledge and Care Practices

Moderator:

Seth Eisen, MD, MSc

Director, Health Services Research and Development

& Years of **DISCOVERY,
INNOVATION,
ADVANCEMENT**
For Veterans

VETERANS AFFAIRS RESEARCH & DEVELOPMENT





Veterans Health Administration
Research & Development

Improving Veterans' Lives www.research.va.gov

Stroke Rehabilitation

Robert L. Ruff, M.D., Ph.D.

Janis Daly, Ph.D.

Department Veterans Affairs Medical Center in Cleveland
FES Center – A Rehabilitation Research and Development
Center of Excellence

& Years of **DISCOVERY,
INNOVATION,
ADVANCEMENT**
For Veterans

VETERANS AFFAIRS RESEARCH & DEVELOPMENT

Stroke Rehabilitation

- Stroke is:
 1. The major cause of neurological disability among adults.
 2. The second leading cause of overall adult disability.
 3. Many have residual deficits after stroke.



Stroke Rehabilitation

- The first stroke leaves about 30% of patients with a functional motor deficit that compromises their activities of daily life.
- Conventional rehabilitation therapy techniques are not sufficient to restore voluntary motor function such as normal gait for many patients following a cerebral infarction.



Why traditional rehab can fail

1. Stroke survivors cannot volitionally activate muscles rapidly or in the proper timing/sequence for practicing coordinated gait components.
2. Patients continually reinforce abnormal movements during walking.
3. **FES can overcome these issues.**



Definition of FES

(Functional Electrical Stimulation)

- Electrical stimulation of muscle to achieve functional movement of a specific muscle or groups of muscles.
- Rehabilitation technique - enhance recovery of voluntary motor function.
- Neuroprosthesis - replace voluntary motor functions.




Hypothesis for Application of FES to Improve Gait

- FES with intramuscular electrodes can augment motor learning after stroke, resulting in recovery of additional **voluntary** motor function and a more normal gait pattern.
- 32 subjects, 2 groups – one treated with BWSTT the other BWSTT + FES.




Figure 4. Pre/Post Treatment Improvement in Cognitive Motor Planning Time and Level of Cognitive Effort.

A. Pre-Treatment



4a. Pre-Treatment.
Long cognitive Planning time (between two arrows, 2900ms). High cognitive effort (dark blue color, high negative potential -15 to -20)

B. Post-Treatment



4b. Post-Treatment.
Shorter cognitive Planning time (2500ms). Lower cognitive effort level (lighter blue color).


Key:  Cognitive Motor Planning Onset  Movement onset

Note:


1. Time to Action reduced
2. Cerebral Activity more focused

Intra-Limb Hip/Knee Angle-Angle Plot FES Improves Consistency of Movement


Control Subject (no Stroke)



Stroke Subject Before Treatment




Stroke Subject after FES-IM Gait Treatment



Hip Angle (degrees)

Subjects who received FES did more



Subject

- Age 69
- Four years prior he had a left hemisphere infarct involving the corona radiata
- He had a right hemiparesis and impaired proprioception on the right
- His wife was not able to manage him at home and hence he was relegated to a nursing home



Functional State

- Not able to walk alone with cane or walker.
- Fell often due to instability of right lower extremity.



Note Improved Knee Function Pre- vs Post-Treatment



Summary

- Rehab enables people to regain function.
- Rehab is an essential part of stroke treatment.
- FES can synergize with other Rehab modalities to enhance recovery.



Years of DISCOVERY,
INNOVATION, 
ADVANCEMENT
For Veterans

VETERANS AFFAIRS RESEARCH & DEVELOPMENT



Veterans Health Administration
Research & Development

Improving Veterans' Lives www.research.va.gov

Kidney Function


Edward J. Weinman, MD

& Years of **DISCOVERY,**
INNOVATION, &
ADVANCEMENT
For Veterans


VETERANS AFFAIRS RESEARCH & DEVELOPMENT



Sodium-Hydrogen Exchange (NHE)




**Hypertension
Diabetes Mellitus
Cell Growth and Cancer
Cell Death (MI, CVA)**




NHERF Binding Proteins

- **Transporters and Channels:**
 - NHE
 - Npt2a
 - CFTR
- **Hormone Receptors:**
 - β 2-Adrenergic Receptor
 - PTH Receptor
 - PDGF Receptor





Representative Kidneys Stained for Calcium from Wild-Type and NHERF-1 Null Mice



Mutations in Npt2 Associated with Nephrolithiasis

Nephrolithiasis and Osteoporosis Associated with Hypophosphatemia Caused by Mutations in the Type 2a Sodium–Phosphate Cotransporter

NEJM 347:983-991, 2002

Dominique Prié, M.D., Ph.D., Virginie Huart, M.S., Naziha Bakouh, M.S., Gabrielle Planelles, M.D., Ph.D., Olivier Dellis, Ph.D., Bénédicte Gérard, D.Pharm., Philippe Hulin, M.S., François Benqué-Blanchet, D.Pharm., Caroline Silve, M.D., Ph.D., Bernard Grandchamp, M.D., Ph.D., and Gérard Friedlander, M.D., Ph.D.



NHERF Associated Diseases

1. Psoriasis
2. Schizophrenia
3. Nerve Deafness
4. Aggressive Estrogen Receptor Positive Breast Cancer
5. Nephrolithiasis



Years of DISCOVERY,
INNOVATION, 
ADVANCEMENT

For Veterans

VETERANS AFFAIRS RESEARCH & DEVELOPMENT

The Brain in Liver Disease

- **Hepatic encephalopathy**


- **Chronic**


- Altered mood, behavior, personality; confusion, and decreased cognitive abilities
 - Usually occurs in the setting of cirrhosis
 - Important socio-economic impact

- **Acute**

- Rapid onset of seizures and coma
 - Usually after viral hepatitis; acetaminophen toxicity and other liver toxins; end-stage cirrhosis
 - Often lethal









Astrocyte


Neuron

Neuron







chronic HE




acute HE





Normal



Acute HE

Events Triggered by Ammonia

- Evidence of oxidative stress (OS)
- Mitochondrial permeability transition
- Mitogen-activated protein kinases
- NF-kappaB (inflammation)
- NKCC (ion transporter)
- Aquaporin-4 levels (water channel)




Potential Therapies

- Interference with ammonia metabolism: histidine
- OS: antioxidants
- mPT: cyclosporin
- MAPKs: inhibitors
- NF-kappaB: BAY 11-7082
- NKCC: bumetanide



Central Pontine Myelinolysis



Years of DISCOVERY,
INNOVATION, 
ADVANCEMENT

For Veterans

VETERANS AFFAIRS RESEARCH & DEVELOPMENT



Veterans Health Administration
Research & Development

Improving Veterans' Lives www.research.va.gov

Effect of CPAP on GWI Symptoms

Mohammad M. Amin, MD

Pulmonary, Critical Care and Sleep Division
Assistant Professor, Stony Brook University
Staff physician, VAMC, Northport NY

& Years of **DISCOVERY,
INNOVATION,
ADVANCEMENT**
For Veterans

VETERANS AFFAIRS RESEARCH & DEVELOPMENT



Background

- Veterans of the first Gulf War experience the symptoms of the *functional somatic syndromes*, including: headaches, widespread pain, cognitive difficulties, fatigue and gastrointestinal complaints.
- My involvement with this research began with the recognition that pharyngeal collapse during sleep plays a role in the symptoms of the functional somatic syndromes.



Pharyngeal Collapse with Inspiratory Flow Limitation




Veteran with GWI

Obstructive Sleep Apnea



Obstructive Sleep Apnea

Nasal Continuous Positive Airway Pressure
(nasal CPAP)



- *Hypothesis* : GWI veterans have Inspiratory Flow Limitation (IFL) during sleep and its correction will result in an improvement of sleep complaints and other functional symptoms.

Objectives:

1. GWI veterans have increased IFL compared to asymptomatic Gulf War veterans (cross sectional study)
2. Relief of IFL results in improvement of GWI Veteran's symptoms (longitudinal study)



Study Protocol

1. Initial enrollment and verification of GWI status.
2. First FNSS
3. Second FNSS with supra-glottic catheter to measure effort and pneumotachography to measure flow / CPAP titration.
4. Randomization to receive either therapeutic CPAP or sham CPAP for three weeks.
5. Third FNSS on their assigned CPAP.



Daily
questionnaires
for 1 week

Daily
questionnaires
for 1 week

1 7 14 21 28

CPAP trial either with
Therapeutic or Sham

12 subjects in each arm

Recruitment

- By advertisement, Veterans must have been deployed to the theater of operations between 8/90 and 8/91 and have the following 3 symptoms beginning after 8/90, lasting at least 6 months and present at the time of screening.
- All 3 symptoms must be unexplained by any clearly defined organic illness and intentionally sleep complaints were not screened and not part of inclusion criteria.



Results of Treatment Trial

All of the 18 GWI Veterans who qualified for the study demonstrated pharyngeal collapse during sleep

After 3 weeks on therapeutic CPAP participants experienced:


- A 37 % improvement of pain VAS score ($p=0.002$)
- A 49 % improvement of Fatigue Severity Scale score ($p=0.0002$)
- A 44% improvement of cognitive VAS score ($p=0.014$)
- A 43% improvement of PSQI score ($p=0.007$)

The p-values are compared to the sham group who generally experienced mild worsening of symptoms.




Control Group

Recruited 11 healthy controls Gulf War Veterans without symptoms of GWI and compare their upper airway dynamics to the 18 Veterans with GWI. The two samples were matched for age and BMI. All of the participants were registered in the Gulf War Veterans Registry.



Control



GWI Participant

Conclusion

- Our findings in this pilot study suggest that pharyngeal collapse during sleep is common among Veterans with GWI and contributes to their symptoms.
- GWI Veterans may benefit of long term utilization of CPAP, we need a large scale VA cooperative study to supports results of this pilot study.
- Acknowledgement to DVA Career Development Award



Years of **DISCOVERY,**
INNOVATION, 
ADVANCEMENT

For Veterans

VETERANS AFFAIRS RESEARCH & DEVELOPMENT



Veterans Health Administration
Research & Development

Improving Veterans' Lives www.research.va.gov

From Research to Clinic: Computer Support for Evidence-Based Care

Mary K. Goldstein, MD, MSc

Director, Geriatrics Research Education & Clinical Center
VA Palo Alto Health Care System
and Professor of Medicine, Stanford University

& Years of **DISCOVERY,
INNOVATION,
ADVANCEMENT**
For Veterans

VETERANS AFFAIRS RESEARCH & DEVELOPMENT



Veterans Deserve the Best

- Clinicians want to
 - Keep up with the latest research
 - Have patient data readily available
 - Have tools to visualize complex clinical information





- Patients are complex:
 - Many diagnoses
 - Many medications
- Medical Literature is huge
- Link information technology with clinical care
 - Information highly tailored to the patient being seen
 - Presented quickly to the clinician within the workflow



Hypertension is Common





85 Years



85 Years

Clinical Decision Support (CDS)

Research goals:

- Rapidly present pertinent information about individual patients to the clinician
- Rapidly provide evidence-based advice
- Account for clinical complexity



ATHENA- Hypertension (HTN)



ATHENA-Hypertension: Building the “Knowledge Base”

athena_hypertension Protégé-2000 (C:\ATHENA-HTN-Demo\domain_model\athena_hypertension.ppr)

Project Edit Window Help PAL Constraints

Classes Forms PAL Constraints


Classes define concepts in the domain

Slots define attributes and relationships

Facets define constraints on slots

Name	Type	Cardinality	Other Facets
goal	Instance	multiple	classes={Conditional_Goal}
clinical_algorithm	Instance	single	classes={Management_Diagram}
version	String	single	
eligibility_criteria	Instance	multiple	classes={Criterion}
authors	String	multiple	
patient_characterization	Class	multiple	parents={Diagnostic_Class}
title	String	single	
primary	Boolean	single	
reference	Instance	multiple	
label	String	required	

From Clinical Scenarios to Treatment Recommendations





Combining Patient Data with Clinical Knowledge

Individual Patient
Clinical Information

Information Display for
Clinicians about
Individual Patient

Clinical Knowledge in
ATHENA- HTN



JAMIA 2002, 2004






85 Years

ATHENA-HTN Implementation

Information displayed to providers



Clinician Response to ATHENA-HTN

- Use ATHENA-HTN extensively.
 - Speaks to usability and usefulness.
- Report ATHENA-Hypertension makes a difference in their medication prescribing.
- ATHENA-Hypertension continues to improve, based on user comments.



Acknowledgments

- Support: VA Health Services Research & Development (HSR&D) and National Library of Medicine (NLM)
- Brian Hoffman, MD co-principal investigator
- Collaborators Eugene Oddone MD, Hayden Bosworth PhD
- Stanford BioMedical Informatics Research (BMIR) EON Group: Mark Musen, Samson Tu, Ravi Shankar, Martin O'Connor, Aneel Advani
- ATHENA Group at VA Palo Alto: Bob Coleman, Susana Martins, Grace Yeh, Dallas Chambers, Dan Wang
- Former Trainees: Albert Chan, S. Nicki Hastings, Herb Szeto, Melissa Fischer, Michael Steinmann, Steve Lai, Nancy Lin
- Other collaborators/advisors: Lars Osterberg, Howard Strasberg, Michael Shlipak, Paul Heidenreich, Michael Gould, Paul Conlin, Denise Hynes, James Schlosser, and others
- VISN Collaborative MAVERIC staff and other VISN 1 Colleagues
- VA OI&T (formerly IRMS)
- Statisticians: Phil Lavori and Alex Sox-Harris (3-site study); Tyson Holmes (VISN 1 collaborative)
-And many others who have contributed to projects



Future Directions

- Add More Disease Guidelines
 - Diabetes, chronic kidney disease, heart failure
- Add clinical information from free-text portions of the electronic health record

Summary

Improve health care for Veterans



Years of DISCOVERY,
INNOVATION, 
ADVANCEMENT

For Veterans

VETERANS AFFAIRS RESEARCH & DEVELOPMENT